A multi-center, Open, randomized, Phase I/II clinical trial to evaluate the safety and efficacy of combined maintenance of rituximab and cytokine-induced killer cells in elderly high-risk DLBCL(Diffuse Large B-Cell Lymphoma) patients responding to the first R-CHOP treatment